MAIA CEO granted 800,000 stock options

MAIA Biotechnology, Inc. reported that Chief Executive Officer and 10% owner Vitoc Vlad received a grant of 800,000 stock options on May 29, 2026 under the company’s 2021 Equity Incentive Plan.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. reported that Chief Executive Officer and 10% owner Vitoc Vlad received a grant of 800,000 stock options on May 29, 2026 under the company’s 2021 Equity Incentive Plan. These options allow him to buy common stock at an exercise price of $1.39 per share until May 29, 2036.

The grant is a compensation award rather than an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting monthly over the following 36 months, aligning his incentives with longer-term company performance.

Insider Trade Summary

Grant/Award: 800,000 shares

Grant/Award 1 txn

Insider Vitoc Vlad

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	800,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 800,000 contracts (Direct)

Footnotes (1)

1. F1. The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

Key Figures

Stock options granted: 800,000 options Exercise price: $1.39 per share Expiration date: May 29, 2036 +3 more

6 metrics

Stock options granted 800,000 options Grant to CEO Vitoc Vlad on May 29, 2026

Exercise price $1.39 per share Strike price for MAIA common stock under options

Expiration date May 29, 2036 Final date to exercise granted options

Initial vesting tranche 25% of options Vests on first anniversary of grant date

Remaining vesting period 36 months Monthly vesting after first anniversary

Underlying shares 800,000 shares Common stock underlying granted options

Key Terms

Stock Options, 2021 Equity Incentive Plan, vesting schedule, exercise price, +1 more

5 terms

Stock Options financial

"The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

vesting schedule financial

"representing the right to buy shares of common stock, vest on a 4-year vesting schedule..."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

exercise price financial

"conversion or exercise price of 1.3900 for the stock options..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant, award, or other acquisition financial

"transaction code description indicates Grant, award, or other acquisition."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA (MAIA) report in this Form 4?

MAIA reported that CEO and 10% owner Vitoc Vlad received a grant of 800,000 stock options. These options are part of his compensation and give him the right to buy MAIA common stock at a fixed exercise price.

How many MAIA (MAIA) stock options were granted to CEO Vitoc Vlad?

Vitoc Vlad was granted 800,000 stock options. Each option represents the right to purchase one share of MAIA common stock, subject to vesting conditions and an exercise price set at the time of grant.

What is the exercise price of Vitoc Vlad’s MAIA (MAIA) stock options?

The stock options have an exercise price of $1.39 per share. This means Vlad can buy MAIA common stock at $1.39, once the options vest and before they expire on the stated expiration date.

When do the MAIA (MAIA) stock options granted to Vitoc Vlad vest?

The options vest over four years. Twenty-five percent vest on the first anniversary of the May 29, 2026 grant date, and the remaining 75% vest in equal monthly installments over the next 36 months, encouraging long-term alignment.

Are Vitoc Vlad’s MAIA (MAIA) stock options an open-market purchase?

No. The filing describes the transaction as a grant or award acquisition under MAIA’s 2021 Equity Incentive Plan. It is part of executive compensation, not an open-market share purchase on a stock exchange.

What is the expiration date of the MAIA (MAIA) stock options granted to Vitoc Vlad?

The options expire on May 29, 2036. If they are not exercised by that date, the right to buy MAIA common stock at the $1.39 exercise price will lapse, and the options will no longer be usable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 08:54 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitoc Vlad

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.39	05/29/2026		A		800,000		(1)	05/29/2036	Common Stock	800,000	$0	800,000	D

Explanation of Responses:

1. The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

	/s/ Vlad Vitoc	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)